TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of “Moderate Buy” from Brokerages

TG Therapeutics, Inc. (NASDAQ:TGTX) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $50.00.

TGTX has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TG Therapeutics in a report on Wednesday, January 14th. B. Riley Financial upgraded shares of TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. Wall Street Zen cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reiterated a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday, December 29th. Finally, JPMorgan Chase & Co. dropped their price target on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd.

Insider Transactions at TG Therapeutics

In related news, Director Yann Echelard sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $32.57, for a total value of $162,850.00. Following the completion of the sale, the director directly owned 223,816 shares in the company, valued at $7,289,687.12. The trade was a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 10.64% of the stock is currently owned by company insiders.

Institutional Trading of TG Therapeutics

Institutional investors have recently made changes to their positions in the business. Johnson Financial Group Inc. acquired a new stake in TG Therapeutics during the 2nd quarter worth about $25,000. Danske Bank A S acquired a new stake in shares of TG Therapeutics during the 3rd quarter valued at about $25,000. Optiver Holding B.V. raised its stake in shares of TG Therapeutics by 3,485.7% during the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 732 shares during the period. Bessemer Group Inc. lifted its holdings in TG Therapeutics by 117.1% during the third quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 486 shares in the last quarter. Finally, Salomon & Ludwin LLC acquired a new stake in TG Therapeutics in the 3rd quarter worth about $34,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Up 0.3%

Shares of TGTX opened at $28.50 on Friday. The stock has a market capitalization of $4.52 billion, a price-to-earnings ratio of 10.25 and a beta of 1.85. The stock has a fifty day moving average of $30.09 and a 200-day moving average of $31.49. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.89 and a current ratio of 3.82. TG Therapeutics has a 52 week low of $25.28 and a 52 week high of $46.48.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.